IL-17 can cause in synaptic dysfunction and impairments in short-term memory in AD mouse models, which neutralization was sufficient to rescue Aβ-induced neuroinflammation and hippocampal glutamatergic dysfunction in early stages of disease with a mechanism that is independent of Aβ and Tau pathology or blood–brain barrier (BBB) disruption (Brigas et al., 2021; Cristiano et al., 2019). This evidence concerns the gene MAPT and Alzheimer disease.